The 23rd Annual Post-ASH Educational meeting provides clinicians with up‑to‑date insights from ASH 2025, covering advances in haematological malignancies and benign Haematology. It is intended for consultants, trainees, specialist nurses, pharmacists and allied professionals involved in Haematology care and research.
Agenda and registration information can be found here:
The agenda spans major developments across malignant and non‑malignant haematology, including:
Updates from UKCHART and the British Society for Haematology
Front‑line therapy in CLL
MRD‑adapted treatment discontinuation in myeloma
Cellular therapies in sickle cell disease and thalassaemia
CAR‑T therapy in DLBCL (second‑ and third‑line)
Bispecific antibodies in DLBCL
Advances in aplastic anaemia
Attendees should expect to:
Understand key clinical updates and practice‑changing data from ASH 2025
Compare expert perspectives through structured debates on myeloma and DLBCL treatment strategies
Gain insight into emerging cellular therapies and their clinical application
Strengthen knowledge of evolving standards of care across haematology subspecialties
Information to Know Before the Event:
The meeting runs 9:00–16:20 with multiple breaks for networking and exhibition stands.
The event is hosted by the Royal Wolverhampton NHS Trust on behalf of UKCHART.
Please direct email queries to: [email protected]
